Home Featured Page 152

Featured

Latest

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

Can Psilocybin Treat Obesity? New Evidence, Future Directions

Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression...

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent...

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient...

PT345 – Steve Thayer, Ph.D. – Vital Psychedelic Conversations

Buried Treasure: How Does Psilocybin Reduce Compulsivity?

Field Trip Health Ltd. Schedules Fiscal First Quarter 2023 Conference Call...

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley...

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

1...151152153...300 Page 152 of 300

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

Can Psilocybin Treat Obesity? New Evidence, Future Directions

Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression...

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent...

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient...

PT345 – Steve Thayer, Ph.D. – Vital Psychedelic Conversations

Buried Treasure: How Does Psilocybin Reduce Compulsivity?

Field Trip Health Ltd. Schedules Fiscal First Quarter 2023 Conference Call...

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley...

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

EDITOR PICKS

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY